LG Life Sciences’ Novel HBV Treatment Proven for Its Efficacy and Safety

Published: 2004-12-16 07:00:00

Updated: 2004-12-16 07:00:00

LG Life Sciences, Ltd (LGLS) reported the interim results from the current Phase 2 clinical trial of LB80380, regarded as the next generation treatment for hepatitis B virus (HBV) infection. The results were presented at the Asia Pacific Association for the Study of the Liver (APASL) conference ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK